Together with leading international experts, we reflect on a quarter century of clinical experience, compare cutting-edge technologies, and define the future of stereotactic treatment in Belgium.
Join us on this day on a journey of insight, exchange, and progress as we shape the next era of radiosurgery.The Radiotherapy Department at UZ Brussel provides the most personalized radiotherapy for each individual patient in Belgium. By continuously investing in advanced technologies, we can offer safe stereotactic brain radiosurgery and markerless stereotactic body radiotherapy, delivering highly precise, state-of-the-art treatments in fewer fractions, while minimizing side effects and optimizing outcomes.
Our commitment to excellence goes beyond clinical care. Grounded in a strong research foundation, we focus on developing and implementing the most modern radiation techniques and biological concepts. This approach not only enhances treatment precision but also deepens our understanding of tumor biology, leading to innovative strategies in cancer care.
Programs like our Spearhead Strategic Research Program demonstrate the societal value of our work, improving both medical practice and patient quality of life. By integrating cutting-edge clinical care with impactful scientific discovery, we strive to set a global standard in radiotherapy-oncology, ensuring patients and their families receive the best possible care at every stage of their journey.
When it comes to brain irradiation, UZ Brussel draws on 25 years of experience in radiosurgery and stereotactic radiotherapy. Precise patient positioning and immobilization, along with high-accuracy tumor localization, are essential. To achieve this, we rely on the TrueBeam system powered by Novalis technology, in collaboration with our long-standing partners Brainlab (Munich, Germany) and Varian (California, USA).
Together, we work to develop new techniques, validate pre-clinical systems, and conduct joint research. This strong partnership continues to drive both technological innovation and clinical advancement. Today, we can treat all malignant and benign brain disorders suitable for radiotherapy with high precision and minimal toxicity.
This event is eligible for continuing education accreditation.